Combivent Respimat costs between $470 and $620 per inhaler at retail pharmacies without insurance, making it one of the pricier rescue inhalers on the market. That high price comes down to three reinforcing factors: there is no generic version available, the device itself is complex and patented, and a single manufacturer controls the entire supply.
No Generic Exists Yet
The most direct reason Combivent Respimat is expensive is that the FDA has not approved a generic version. Without competition, Boehringer Ingelheim sets the price. The last qualifying patent on the drug doesn’t expire until October 2030, which means generic manufacturers can’t legally produce a copy for several more years. Even after that date, developing a generic inhaler takes additional time because companies must prove their device delivers the medication to the lungs in the same way the original does.
This is different from a simple pill, where a generic manufacturer only needs to match the active ingredient. Inhaler generics require matching the drug formulation, the particle size, and the device performance all at once. That higher regulatory bar has historically delayed generic inhalers well beyond patent expiration.
The Respimat Device Is Difficult to Replicate
Combivent Respimat uses a “soft mist” inhaler rather than a standard pressurized canister. Inside the device, liquid medication is forced through two tiny nozzle channels, each only 8 micrometers wide, angled so the jets collide at 90 degrees. That collision breaks the liquid into an ultra-fine mist you can inhale slowly and deeply without needing to coordinate a fast breath with a spray.
Manufacturing nozzles at that microscopic scale requires precision engineering that conventional metered-dose inhalers don’t demand. The device also contains a spring mechanism that generates the force to push liquid through those channels. All of this adds production cost compared to a basic aerosol canister, and it makes it harder for competitors to develop a substitute device that performs identically.
Brand-Only Pricing in a Small Market
Combivent Respimat combines two bronchodilators (albuterol and ipratropium) in a single inhaler, primarily prescribed for COPD. That’s a narrower market than standalone albuterol inhalers used by tens of millions of asthma patients. A smaller patient pool gives the manufacturer less incentive to lower prices voluntarily, and it gives generic companies less financial motivation to invest in the complex approval process for a competing product.
Pharmacy benefit managers also play a role. These middlemen negotiate rebates with manufacturers behind the scenes, and the “list price” you see at the pharmacy counter reflects those negotiations. Boehringer Ingelheim has acknowledged it cannot control fees added by pharmacy benefit managers, which can inflate what you actually pay.
The $35 Price Cap and Who It Covers
Boehringer Ingelheim has voluntarily capped out-of-pocket costs for its inhalers at $35 per month for eligible patients. This cap applies at retail pharmacies and is designed to help people who are uninsured or underinsured. If you have commercial insurance, your copay may already be lower than the retail price, but the cap can still reduce costs if your plan’s cost-sharing is high.
The company also offers separate patient assistance programs, discounts, and rebates. Eligibility varies, so checking Boehringer Ingelheim’s website or asking your pharmacist is the fastest way to find out if you qualify. Discount platforms like GoodRx list coupon prices ranging from roughly $470 to $540 depending on the pharmacy, which can help if you’re paying cash.
Lower-Cost Alternatives Worth Asking About
Because Combivent Respimat combines two drugs, one option is using each component separately. Generic albuterol inhalers are widely available and inexpensive. Ipratropium bromide inhalers also come in generic form. Using two separate inhalers is less convenient, but the combined cost is typically a fraction of what Combivent Respimat costs. Your prescriber can help you decide whether splitting the medications makes sense for your situation.
For maintenance COPD treatment (as opposed to rescue use), tiotropium is available as a lower-cost generic. It works differently than the ipratropium in Combivent, lasting a full 24 hours per dose, and may reduce how often you need a rescue inhaler in the first place. Switching medications always involves trade-offs, but if cost is a barrier to using your inhaler consistently, a less expensive regimen you actually take is better than an expensive one you skip.